Alexander Kamb, Ph.D.
Founder and Chief Scientific Officer
Dr. Alexander “Sasha” Kamb founded A2 Biotherapeutics to fulfill the potential of cell therapy to treat disease and improve patients’ lives. He brings decades of experience working with various drug modalities to his role as chief scientific officer, where he is focused on combining A2 Bio’s best-in-class technology with a new target class, while building a team of world-class scientists to advance the company’s first-in-class T cell therapies for solid tumors. Before founding A2 Bio, Sasha worked at Amgen from 2006 to 2017, most recently serving as senior vice president and head of discovery research. Prior to that, he directed Amgen’s oncology research group and neuroscience therapeutic area. In 1996, Sasha founded Arcaris (acquired by Deltagen Proteomics in 2001) and served as the company’s president, CEO and CSO, directing research and business efforts focused on the discovery of novel pharmaceutical targets. Earlier in his career, he was director of research at Myriad Genetics and led groups that identified genes responsible for familial melanoma and breast cancer.